Bone-protecting drugs reduce pain and fractures in metastatic breast cancer

July 19, 2005

When breast cancer spreads to bones, relatively new protective drugs called bisphosphonates can reduce skeletal damage, says a new systematic review of previous studies. While the new treatment approach does not improve survival rates, it can minimize disabling fractures, spinal cord compression and pain.

The bone-protecting medications are already in common used among patients with osteoporosis and multiple myeloma, a cancer that affects bone marrow. The skeleton is the most common site for the spread of breast cancer, affecting more than half of women for whom the cancer spreads.

"Bisphosphonates should be part of standard therapy in women with advanced breast cancer and clinically evident bone metastases," recommends lead author Dr. Nick Pavlakis, an oncologist at the University of Sydney in Australia. The report emphasizes that bisphosphonate treatment should be added to conventional anti-cancer treatments such as chemotherapy and hormone therapy.

There is "strong evidence," adds Pavlakis, that bisphosphonate use can "reduce the likelihood of new skeletal events, the rate of events and possibly bone pain."

"Until recently, the management of symptomatic bone disease depended on analgesics, radiotherapy, endocrine therapy, and chemotherapy," says the review. "Despite these frequently effective treatments, progressive skeletal destruction often leads to ongoing symptoms and deterioration of quality of life." The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic. The authors analyzed results from 21 randomized controlled trials that evaluated oral or intravenous bisphosphonates in addition to hormone therapy or chemotherapy. Fifteen studies comprised 5,187 women with advanced breast cancer and bone metastases.

All 12 studies that evaluated the rate of bone problems revealed reductions ranging from 14 to 48 percent with bisphosphonate treatment. The study treatment also led to significant lessening of bone pain in seven studies.

The remaining six studies focused on 1,973 women with breast cancer but without known bone metastases. In these groups, bisphosphonate treatment did not seem to affect the occurrence of new metastases or skeletal events.

Side effects of bisphosphonates were generally mild and infrequent. They included stomach upset and occasional fever.

Pavlakis says there are several questions related to bisphosphonate treatment that remain unanswered. "The key area open to research is the use of bisphosphonates in early breast cancer," he says.

"There is no evidence currently available to definitely confirm that one bisphosphonate is better than another, mainly because the appropriate studies have not been done," he adds.
The review notes that Pavlakis has received study grants and/or speaking honoraria from Sanofi-Aventis, Roche, and Novartis Pharmaceuticals.

Health Behavior News Service: 202-387-2829 or Interviews: Nick Pavlakis, University of Sydney, tel. 61-299-265-020, email To receive a full copy of the review, contact Julia Lampam at 44-124-377-0668 or

Pavlakis N, Schmidt RL, Stockler M. Biphosphonates for Breast Cancer. The Cochrane Database of Systematic Reviews 2005, Issue 3.

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit for more information.

Center for Advancing Health

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to